These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21209853)

  • 1. The cooperation between hMena overexpression and HER2 signalling in breast cancer.
    Di Modugno F; Mottolese M; DeMonte L; Trono P; Balsamo M; Conidi A; Melucci E; Terrenato I; Belleudi F; Torrisi MR; Alessio M; Santoni A; Nisticò P
    PLoS One; 2010 Dec; 5(12):e15852. PubMed ID: 21209853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
    Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
    Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines.
    Di Modugno F; DeMonte L; Balsamo M; Bronzi G; Nicotra MR; Alessio M; Jager E; Condeelis JS; Santoni A; Natali PG; Nisticò P
    Cancer Res; 2007 Mar; 67(6):2657-65. PubMed ID: 17363586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors.
    Di Modugno F; Iapicca P; Boudreau A; Mottolese M; Terrenato I; Perracchio L; Carstens RP; Santoni A; Bissell MJ; Nisticò P
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19280-5. PubMed ID: 23129656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines.
    Pino MS; Balsamo M; Di Modugno F; Mottolese M; Alessio M; Melucci E; Milella M; McConkey DJ; Philippar U; Gertler FB; Natali PG; Nisticò P
    Clin Cancer Res; 2008 Aug; 14(15):4943-50. PubMed ID: 18676769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative expression of hMena11a and hMenaINV splice isoforms is a useful biomarker in development and progression of human breast carcinoma.
    Tanaka N; Yoshida H; Suzuki Y; Harigaya K
    Int J Oncol; 2014 Nov; 45(5):1921-8. PubMed ID: 25109497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.
    Di Modugno F; Mottolese M; Di Benedetto A; Conidi A; Novelli F; Perracchio L; Venturo I; Botti C; Jager E; Santoni A; Natali PG; Nisticò P
    Clin Cancer Res; 2006 Mar; 12(5):1470-8. PubMed ID: 16533770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of human ortholog of mammalian enabled (hMena) is associated with the expression of mutant p53 protein in human breast cancers.
    Toyoda A; Yokota A; Saito T; Kawana H; Higashi M; Suzuki Y; Tanaka T; Kitagawa M; Harigaya K
    Int J Oncol; 2011 Jan; 38(1):89-96. PubMed ID: 21109929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. hMENA(11a), a hMENA isoform sending survival signals.
    Trono P; Di Modugno F; Nisticò P
    Mol Cell Oncol; 2016 Mar; 3(2):e1083648. PubMed ID: 27308605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC.
    Trono P; Tocci A; Palermo B; Di Carlo A; D'Ambrosio L; D'Andrea D; Di Modugno F; De Nicola F; Goeman F; Corleone G; Warren S; Paolini F; Panetta M; Sperduti I; Baldari S; Visca P; Carpano S; Cappuzzo F; Russo V; Tripodo C; Zucali P; Gregorc V; Marchesi F; Nistico P
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37612043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. hMENA isoforms impact NSCLC patient outcome through fibronectin/β1 integrin axis.
    Di Modugno F; Spada S; Palermo B; Visca P; Iapicca P; Di Carlo A; Antoniani B; Sperduti I; Di Benedetto A; Terrenato I; Mottolese M; Gandolfi F; Facciolo F; Chen EI; Schwartz MA; Santoni A; Bissell MJ; Nisticò P
    Oncogene; 2018 Oct; 37(42):5605-5617. PubMed ID: 29907768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
    Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
    J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome.
    Melchionna R; Iapicca P; Di Modugno F; Trono P; Sperduti I; Fassan M; Cataldo I; Rusev BC; Lawlor RT; Diodoro MG; Milella M; Grazi GL; Bissell MJ; Scarpa A; Nisticò P
    Oncoimmunology; 2016; 5(12):e1221556. PubMed ID: 28123868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling.
    Brennan K; McSherry EA; Hudson L; Kay EW; Hill AD; Young LS; Hopkins AM
    Oncogene; 2013 May; 32(22):2799-804. PubMed ID: 22751120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
    Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
    Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.
    Di Modugno F; Di Carlo A; Spada S; Palermo B; D'Ambrosio L; D'Andrea D; Morello G; Belmonte B; Sperduti I; Balzano V; Gallo E; Melchionna R; Panetta M; Campo G; De Nicola F; Goeman F; Antoniani B; Carpano S; Frigè G; Warren S; Gallina F; Lambrechts D; Xiong J; Vincent BG; Wheeler N; Bortone DS; Cappuzzo F; Facciolo F; Tripodo C; Visca P; Nisticò P
    EBioMedicine; 2024 Mar; 101():105003. PubMed ID: 38340557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant expression of human ortholog of mammalian enabled (hMena) in human colorectal carcinomas: implications for its role in tumor progression.
    Toyoda A; Kawana H; Azuhata K; Yu J; Omata A; Kishi H; Higashi M; Harigaya K
    Int J Oncol; 2009 Jan; 34(1):53-60. PubMed ID: 19082477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
    Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
    Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLMEEMSAL epitope common in different isoforms of hMena elicits in vitro activation of cytotoxic T cells and stimulates specific antitumor immunity in BALB/c mice.
    Don-López CA; Monroy-García A; Weiss-Steider B; Rocha-Zavaleta L; Hernández-Montes J; García-Rocha R; Mora-García ML
    Int Immunopharmacol; 2018 Mar; 56():291-300. PubMed ID: 29414664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.
    Helms MW; Kemming D; Contag CH; Pospisil H; Bartkowiak K; Wang A; Chang SY; Buerger H; Brandt BH
    Cancer Res; 2009 Jun; 69(12):5049-56. PubMed ID: 19491269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.